Breast cancer remains one of the leading causes of cancer-related mortality worldwide, with early detection being paramount to successful treatment and patient survival. Traditional diagnostic pathways often involve a combination of mammography, ultrasound, and magnetic resonance imaging (MRI), followed by invasive procedures like biopsies to confirm malignancy. However, the integration of these diverse imaging modalities for comprehensive risk assessment and subtype classification has posed significant challenges, both in terms of data heterogeneity and clinical applicability. BINDS addresses these challenges by implementing a two-stage diagnostic approach that closely follows current clinical procedures.

The first stage of BINDS utilizes initial assessments with ultrasound and/or mammography to triage patients rapidly. This preliminary screening aids in identifying lesions that warrant further investigation. The design of BINDS in this phase emphasizes speed and accuracy, tailored to scenarios where MRI might not be immediately available or necessary. By effectively stratifying patients, the system optimizes resource allocation and ensures patients at higher risk receive timely, more detailed diagnostics.

In the second stage, BINDS incorporates comprehensive multimodal imaging data including MRI, which provides enhanced soft tissue contrast and functional imaging capabilities. This comprehensive diagnostic operation enables more nuanced classification of breast cancer subtypes, critical for personalized treatment strategies. The integration of MRI data into BINDS allows the system to extract deeper insights from tissue heterogeneity, vascularity, and lesion morphology that are often beyond the reach of ultrasound and mammography alone.

A distinctive innovation within BINDS is its novel radiology-pathology alignment mechanism. This component facilitates the precise extraction of pathology-relevant features from radiological images, bridging the gap between imaging observation and histopathological findings. Such alignment ensures that the deep learning algorithms learn clinically meaningful patterns associated with pathologic outcomes, enhancing the model’s diagnostic specificity and sensitivity. This ability to correlate imaging signatures with histopathology is pivotal for distinguishing between benign and malignant lesions, thereby reducing false positives.

The robustness of BINDS is underpinned by a diverse dataset comprising 27,048 participants drawn from multiple centers and seven publicly available datasets. This extensive and heterogeneous data foundation not only bolsters the generalizability of the system across different clinical settings but also enables flexible combinations of input modalities during both training and validation phases. Such adaptability is crucial for real-world deployment where available diagnostic modalities may vary due to equipment and resource constraints.

BINDS demonstrated striking diagnostic performance, attaining an area under the receiver operating characteristic curve (AUC) of 0.973. This metric reflects exceptional accuracy in distinguishing malignant from benign lesions. The system’s high classification performance has tangible clinical implications; when deployed alongside radiologists, BINDS contributed to reducing unnecessary biopsies of benign lesions by up to 32.4%. This reduction not only eases patient burden and anxiety but also curtails healthcare costs and resource utilization.

The clinical adoption of BINDS also aligns with evolving precision medicine paradigms. By integrating data from multiple imaging modalities and ensuring seamless correlation with pathology, BINDS supports more individualized patient risk profiles and subtype classifications. This granularity enables clinicians to tailor management plans more effectively, optimizing therapeutic outcomes and surveillance strategies.

Moreover, the system’s architecture supports flexible input modality combinations, reflecting its design for diverse clinical environments ranging from resource-rich tertiary centers with access to comprehensive imaging facilities to lower-resource settings where MRI might be inaccessible. This flexibility facilitates scalable diagnostic solutions that can be customized according to institutional capabilities without compromising accuracy.

The development and validation process for BINDS involved interdisciplinary collaboration, harnessing expertise in medical imaging, pathology, data science, and clinical oncology. This confluence of fields was essential in ensuring that the deep learning models are both technically sophisticated and clinically relevant. The system exemplifies how artificial intelligence can be harnessed to bridge the gap between complex biomedical data and practical clinical decision-making.

Looking forward, the implications of BINDS extend beyond breast cancer diagnosis. The architecture and methodology of integrating multimodal imaging with pathology-aligned feature extraction provide a template that could be adapted for other malignancies where multimodal diagnostics are prevalent. Such cross-disease adaptability underscores the potential of deep learning frameworks to revolutionize oncological diagnostics broadly.

In addition to diagnostic accuracy, patient experience is central to the utility of BINDS. By reducing unnecessary biopsies, patients avoid invasive procedures, potential complications, and the psychological distress associated with uncertain diagnoses. This patient-centric impact aligns with broader goals in oncology to harmonize technological advances with improvements in quality of life.

Furthermore, the interpretability of BINDS outputs remains a focus for future development. While deep learning models can sometimes be black boxes, the integration with pathology-informed features enhances transparency and provides clinicians with more insight into the decision rationale. This interpretability fosters clinical trust and facilitates integration into existing workflows.

The work behind BINDS also highlights the importance of large-scale, multi-institutional datasets in training and validating AI-driven diagnostic systems. Diverse data encompassing varying populations, imaging protocols, and pathologies ensure robustness and mitigate bias, thereby supporting equitable diagnostic accuracy across demographic groups.

Finally, BINDS stands as a testament to the transformative potential of artificial intelligence in medicine, especially when thoughtfully designed to complement and enhance clinical expertise. By combining multimodal imaging integration, pathology alignment, and flexible deployment frameworks, BINDS charts a promising course toward more accurate, non-invasive, and accessible breast cancer diagnostics—a critical step in the global fight against breast cancer.

Subject of Research: Breast cancer diagnosis using multimodal imaging and deep learning

Article Title: A deep learning system for non-invasive breast cancer diagnosis with multimodal data

Article References:
Li, Y., Zhang, J., Chen, H. et al. A deep learning system for non-invasive breast cancer diagnosis with multimodal data. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01654-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01654-2

Historically, breast cancer risk evaluations have been predominantly predicated on hereditary factors, including well-characterized genetic mutations, yet these only elucidate a fraction—approximately 6%—of cases. For women without known genetic predisposition or family history, risk stratification has remained imprecise and often reliant on indirect methodologies such as mammographic breast density. These traditional approaches risk misclassification, leading to both over-diagnosis and missed early warning signs. The newly devised platform catalyzes a paradigm shift by delivering a direct, biophysical measure embedded within the cells themselves.

At the heart of this innovation lies a microfluidic device designed to “squeeze” individual epithelial cells through narrow channels, functionally mimicking biomechanical stressors. The platform captures how rapidly and effectively these cells deform and subsequently recover their shape, markers indicative of their mechanical properties—parameters termed as “mechanical age.” This concept, borrowed from material engineering disciplines that study wear and fatigue in metals and polymers, is applied here for the first time to living cells, bridging engineering principles with cellular biology in a novel fusion.

The team’s approach heavily leverages computational advancements through the integration of machine learning algorithms. By training with extensive datasets derived from cells of varying ages and genetic risk profiles, the algorithm quantitatively discerns cells exhibiting premature mechanical aging signatures — cells that, while from younger individuals, present deformation behaviors reminiscent of aged cells. These findings not only validate the mechanical age hypothesis but also correlate directly with heightened breast cancer risk, including in individuals harboring high-risk genetic mutations.

Unlike other cell mechanics measurement techniques, such as atomic force microscopy or advanced optical imaging, the MechanoAge platform circumvents the need for prohibitively expensive and complex instrumentation. Instead, it utilizes widely accessible electronic components akin to those found in common devices, ensuring affordability and scalability. This factor alone holds transformative potential for widespread clinical implementation, democratizing access to early and precise breast cancer risk detection.

The microfluidic device operates on the principle of mechano-node-pore sensing, wherein the translocation of cells through liquid-filled, electronically monitored channels disrupts an electrical current. These disruptions translate into real-time metrics on cellular size, shape, and deformability. Narrow constrictions strategically incorporated in the channels induce mechanical challenge, while the system records recovery dynamics with high temporal resolution. The quantifiable parameters extracted provide an integrative index reflective of cellular health and mechanical resilience.

A particularly revealing outcome of this investigation is the disconnect observed between chronological age and mechanical cellular age. Some younger women’s cells displayed stiffness and prolonged recovery indicative of advanced mechanical aging. This discrepancy uncovers a layer of biological complexity that conventional risk assessment tools overlook, emphasizing the capacity of MechanoAge to identify subtle phenotypic variations that predicate cancer development.

Validation studies using samples from a diverse cohort — comprising healthy individuals, those with familial breast cancer history, and patients with unilateral breast cancer — demonstrated the platform’s accuracy in differentiating high-risk profiles. The derived risk scores closely aligned with known genetic susceptibilities and clinical diagnoses, underscoring the platform’s potential as a precision medicine tool that guides tailored screening regimens.

The collaborative nature of this research, spanning over a decade, merges deep expertise from cancer biology and mechanical engineering. The continuous exchange of insights between these disciplines fostered a holistic understanding vital to advancing from conceptualization to application. Researchers emphasize that this longitudinal partnership was instrumental in achieving these unanticipated yet impactful discoveries.

Looking forward, the MechanoAge platform might reshape breast cancer screening paradigms, enabling earlier, more accurate detection of risk at an individual cell level well before tumors manifest clinically. Such a shift promises to reduce unnecessary interventions while enhancing vigilance for those at genuine heightened risk. Furthermore, with the device’s affordability and portability, it could see deployment beyond specialized centers, reaching underserved populations globally.

This novel assessment method also holds promise beyond cancer, potentially applicable to other age-related diseases where cellular mechanical properties influence pathology. The framework combining microfluidics and artificial intelligence illustrates a broader trend towards integrating engineering innovation with biomedical discovery, heralding a new epoch of personalized medicine driven by cellular phenotyping.

The research was generously supported by multiple grants from the National Institutes of Health and the American Cancer Society, reflecting a critical investment in transformative translational science. The authors disclosed no competing interests, though relevant patent applications underscore the groundbreaking nature of this technology, laying groundwork for future commercialization efforts.

In summation, the MechanoAge platform represents a paradigm shift, advancing breast cancer risk assessment by quantifying the mechanical behavior of single cells. By applying engineering principles to biology, it illuminates hidden dimensions of cellular aging and risk—ushering in an era of individualized, mechanobiologically informed cancer prevention and early detection.

Subject of Research: Cells

Article Title: MechanoAge, a machine learning platform to identify individuals susceptible to breast cancer based on mechanical properties of single cells

News Publication Date: 23-Apr-2026

Image Credits: City of Hope and UC Berkeley

Keywords

Breast cancer, Microfluidics, Engineering, Epidemiology, Personalized medicine, Machine learning, Artificial intelligence